Biotech startup Kyan Therapeutics has raised US$5 million in an oversubscribed pre-series A round led by Altara Ventures.
The Singapore-based firm bagged the funds shortly after receiving positive findings from its clinical study on a guided treatment platform for patients with relapsed and refractory lymphoma.
The fresh funds will be used to help the company establish a commercial lab, fund additional clinical trials, and expand its team.
Kyan, through its tech platforms, aims to identify the best possible combinations of therapies at different dosages for everything from drug development to personalized medicine.
“Singapore is the perfect place for us to set up our new global headquarters, given the access to strategic investors, leading clinical collaborators and great talent,” Hugo Saavedra, Chairman and CEO of Kyan, said in a statement.
Following the fundraise, Gavin Teo, general partner at Altara Ventures, will join Kyan’s board of directors. Seeds Capital and K3 Ventures also participated in the funding round.
See also: Series SEA: Who’s investing in the region’s biotech startups?
Editing by Miguel Cordon
(And yes, we’re serious about ethics and transparency. More information here.)
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.
